PFIZER vs VALIANTLAB: Stock Comparison

Pfizer Limited vs Valiant Laboratories Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Pfizer Limited is the larger company by market capitalisation. Pfizer Limited shows a higher ROE, a higher dividend yield and faster revenue growth, while Valiant Laboratories Limited shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Pfizer Limited and Valiant Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, PFIZER is more favourable on 7 of 11 scored metrics and VALIANTLAB on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PFIZER is the larger company
₹21,490 Cr vs ₹329 Cr
P/E Ratio
VALIANTLAB has a lower P/E
-101.03x vs 29.89x
P/B Ratio
VALIANTLAB has a lower P/B
1.06x vs 5.14x
EPS
PFIZER has higher earnings per share
₹157.72 vs ₹-0.05
Dividend Yield
PFIZER has a higher dividend yield
2.83% vs 0%
Revenue Growth (TTM YoY)
PFIZER has faster revenue growth
6.3% vs 0%
EPS Growth (TTM YoY)
VALIANTLAB has faster EPS growth
0% vs -39.6%
ROE
PFIZER has a higher ROE
19.8% vs -1.05%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricPFIZERVALIANTLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricPFIZERVALIANTLAB
Live Price₹4,710.7₹81.65
Day Change0.39%2.55%
Volume1.2 L87,489
52-Week High₹5,873.5₹100.98
52-Week Low₹4,360.1₹49.51
Distance from 52W High-19.8%-19.14%

Valuation

MetricPFIZERVALIANTLAB
Market Cap₹21,490 Cr₹329 Cr
P/E Ratio29.89x-101.03x
P/B Ratio5.14x1.06x
EPS₹157.72₹-0.05
Book Value₹918.74₹50.08
Dividend Yield2.83%0%

Growth

MetricPFIZERVALIANTLAB
Revenue Growth (TTM YoY)6.3%0%
EPS Growth (TTM YoY)-39.6%0%
Qtr Sales Growth148%
Qtr Profit Growth457%

Profitability & Leverage

MetricPFIZERVALIANTLAB
ROE19.8%-1.05%
ROCE27.2%-0.95%
Net Margin28.67%-1.38%
Operating Margin-12.1%1.12%
Debt to Equity0x0.14x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricPFIZERVALIANTLAB
Promoter Holding63.92%74.94%
FII Holding1.65% 1.16 pp0% 0.2 pp
DII Holding17.8% 0.91 pp0%
Public Holding16.63% 0.26 pp25.06% 0.2 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Pfizer Limited and Valiant Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.